| 摘要 |
CD40 receptor binders, such as G28.5 and CD40L, are used on their own or in conjunction with at least one antineoplastic agent and/or CD40 inducer to treat carcinomas in epithelial cells and prevent epithelial cell proliferation. It is shown that CD40 stimulation in epithelial cells of either normal or neoplastic origin results in growth arrest and enhanced susceptibility to anti-neoplastic agent-induced apoptosis. The antineoplastic agents used are selected from the group including transforming growth factor â, anti-Fas, tumour necrosis factor-á (TNF- á), interferon-ã (IFN-ã), cis-platin, mitomycin C, cyclophosphamide, actinomycin D, doxorubicin, vincristine, etoposide, 5-fluorouracil and methotrexate. The CD40 inducer may be IFN-ã, TNF-á or any other known inducer of CD40 expression. FIG 8 shows the effect of 48 hours treatment with CD40L on the growth of the ovarian carcinoma cell line A2780. The data represents the % decrease in survival relative to untreated controls,
|
